All Posts
FDA Approves OncoSil™ Device for Distal Cholangiocarcinoma
A new treatment option is now available for some patients with distal cholangiocarcinoma (dCCA) in the United States. On August…
Simposio Regional de Houston 2026
El Simposio de Colangiocarcinoma de Houston 2026 reunirá en Houston a destacados expertos, investigadores, profesionales de la salud, pacientes y…
Simposio Regional de Los Ángeles 2026
El Simposio de Colangiocarcinoma de Los Ángeles 2026 reunirá en Los Ángeles a destacados expertos, investigadores, profesionales de la salud,…
In-Person CARE Events: Seattle and Washington, DC/Baltimore
There is strength in connecting with others who understand the experience of cholangiocarcinoma. We are pleased to host two upcoming…
Eve Baker's Legacy Helps Others on their (Cholangio)Paths
Eve Baker is remembered for many remarkable accomplishments and journeys, and her legacy now lives through her support of others.…
Community Champion: Sydney Towle
In 2023, at 23 years old, Sydney Towle was diagnosed with cholangiocarcinoma (CCA). Since her diagnosis, she has courageously shared…
June 30-Mile Challenge Raises $112,351
Together, We Went Far: June 30-Mile Challenge Raises $112,351 Behind every mile logged this June was a name. A person.…
ICRN Investigators Spotlight
Senior InvestigatorShishir Maithel, MD, FACS, FSSO Chief of Surgical Oncology in the Department of SurgeryProfessor, Surgery, Surgical Oncology, William T.…
For my dad
Those you love cannot be lost, because they are always a part of you. This blog is a Father's Day…
Phase 3 FIGHT-302 Results Presented at ASCO 2026 Evaluate Pemigatinib as a Potential First-Line Treatment Approach for Patients with FGFR2 Fusion- or Rearrangement-Positive Cholangiocarcinoma
Incyte's pemigatinib demonstrated a statistically significant improvement in progression-free survival compared with standard chemotherapy FOR IMMEDIATE RELEASEJune 12, 2026Karen TempletonSenior…